Seagen Inc.
CD47 antibodies and uses thereof for treating cancer

Last updated:

Abstract:

Humanized antibodies, including masked antibodies that specifically bind to CD47 are provided. Methods for using anti-CD47 antibodies, including masked antibodies, to modulate activity of (e.g., inhibit proliferation of) a CD47-expressing cell, as well as for the treatment of one or more diseases or disorders (e.g., cancer) associated with CD47-expressing cells, are provided.

Status:
Grant
Type:

Utility

Filling date:

29 Nov 2018

Issue date:

23 Nov 2021